Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arginine for Cancer Prevention
NCT03940053Phase 3Unknown
- Start
- May 2019
- Primary completion
- Aug 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, open-label trial of arginine in cancer (2 arms). Primary endpoint: Incidence of Cancer at 60 months. Status: unknown.
02
Drugs
arginine
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03940053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940053.